UCB Pays $2 Billion for Candid, Accelerating Immune‑Reset Strategy

UCB announced a $2 billion upfront payment to buy Candid Therapeutics, a clinical‑stage biotech focused on bispecific antibodies that direct T cells to eliminate disease‑driving B cells. The deal includes up to $200 million in milestone payments if Candid’s programs meet predefined targets. The acquisition closes after Candid terminated a prior reverse‑merger with Rallybio, triggering a $50 million termination fee to Rallybio.

Candid’s lead candidate, cizutamig, is a T‑cell engager that binds BCMA, a protein on pathogenic B cells. Phase 1 data showed acceptable safety and tolerability, prompting a move to Phase 2 trials in myasthenia gravis and interstitial lung disease. A second candidate, CND261, targets CD19 and is in early clinical testing, with first results expected in the first half of the year. Additional preclinical T‑cell engagers are in the pipeline.

UCB’s CEO Jean‑Christophe Tellier called cizutamig a “potentially transformative asset” that could redefine treatment for severe, underserved immune‑mediated diseases. The purchase complements a recent $80 million Antengene deal that grants UCB exclusive rights to another bispecific antibody for B‑cell disorders, with further milestones worth up to $1.1 billion.

The transaction reflects a broader industry trend: large pharma firms are betting on T‑cell engagers originally developed for cancer to treat autoimmune conditions. Recent examples include Gilead’s $1.7 billion acquisition of Ouro Medicines and Cullinan Therapeutics’ expansion into rheumatoid arthritis and lupus. By securing multiple B‑cell targets—BCMA, CD19, and others—UCB diversifies its immunology portfolio beyond its top seller Bimzelx, which generated about $2.5 billion in 2025 sales.

For patients, the promise of an “immune reset” lies in depleting harmful B cells while allowing new, non‑autoreactive cells to repopulate, potentially delivering durable remission. However, efficacy and durability remain unproven; current evidence is limited to early‑phase safety data, and correlation between B‑cell depletion and long‑term disease control has not yet been established.

Regulatory approval of the acquisition is pending, with closing expected in late Q2 or early Q3 2026. Watch for Phase 2 readouts of cizutamig and the first data from CND261, which will indicate whether UCB’s aggressive push into immune‑reset therapies can translate into marketable treatments.